• Agenus advanced plans for ROBBIN, a global Phase 3 neoadjuvant trial of botensilimab with balstilimab in high-risk Stage II-III MSS colon cancer; first dosing expected in Q1 2027.
• The trial launch follows results already presented from NEST and UNICORN, showing strong tumor clearance before surgery with no recurrences reported at the cutoffs.
• An oversubscribed private placement raised USD 85 million upfront, with milestone-linked warrants for up to USD 255 million to fund execution.
• Management framed the target setting as a large, underserved market, estimating more than USD 7 billion in annual U.S. sales potential.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-336780), on August 06, 2026, and is solely responsible for the information contained therein.